Article

GRAIL Announces Positive Top-Line Results From The Galleri® PATHFINDER 2 Registrational Study

06/26/2025

Cancer Detection and Positive Predictive Value Substantially Higher Than the Previously Published PATHFINDER Study Excerpt from the Press Release: MENLO PARK, Calif., June 18, 2025 /PRNewswire/ — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced positive top-line performance and safety results from…

Read More

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

06/25/2025

Excerpt from the Press Release: REDWOOD CITY, Calif., June 18, 2025 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced new preclinical findings from a 28-day weight loss study in obese non-human primates evaluating BMF-650, the Company’s investigational, next-generation oral small…

Read More

Qlaris Bio Announces Development of Fixed-Dose Combination Therapy with QLS‑111 and Latanoprost for the Treatment of Glaucoma

06/24/2025

Combination therapy seeks to improve intraocular pressure lowering by pairing a novel EVP-targeting agent with prostaglandin analogue standard of care Excerpt from the Press Release: DEDHAM, Mass.–(BUSINESS WIRE)–Qlaris Bio, Inc., a clinical-stage biotechnology company, today announced that it is developing a novel preservative-free, fixed-dose combination (FDC) therapy that combines the company’s lead program, QLS-111, and…

Read More

Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025

06/23/2025

BP1.15205 is a potentially best-in-class OX2R agonist being investigated in narcolepsy and other central disorders of hypersomnolence A first-in-human study is planned to start in 2H 2025; topline clinical data is anticipated in 2026 Excerpt from the Press Release: PLYMOUTH MEETING, Pa.–(BUSINESS WIRE)–Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the presentation of preclinical pharmacological…

Read More

Capstan Therapeutics Announces Initiation of Phase 1 Trial of Lead In Vivo CAR-T Therapy, CPTX2309, for Treating Autoimmune Disease

06/20/2025

Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Capstan Therapeutics, Inc. (“Capstan”), a clinical-stage biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced successful dosing of the first participants in its Phase 1 trial of CPTX2309, Capstan’s lead anti-CD19 in vivo CAR-T candidate, for the…

Read More

BostonGene’s Multiomic AI Platform Uncovers Therapeutic Targets in Invasive Lobular Carcinoma, Wins GRASP Advocate Choice Award at ASCO 2025

06/19/2025

Study Identifies Disease-Specific Targets to Inform Precision Drug Development in Breast Cancer Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced that its poster at the 2025 American Society of Clinical Oncology (ASCO) annual meeting has received the GRASP Advocate Choice Award. The poster,…

Read More

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

06/18/2025

Second-generation norovirus constructs produce statistically significant increases in GI.1 and GII.4 norovirus blocking antibodies (141% and 94%, respectively) compared with first-generation constructs, supporting potential for improved protection against infection – – Vaccine candidates were safe and well-tolerated across all dose groups with no vaccine-related serious adverse events reported – Excerpt from the Press Release: SOUTH…

Read More

Efficient mRNA delivery to resting T cells to reverse HIV latency

06/17/2025

Excerpt from the Press Release: Abstract A major hurdle to curing HIV is the persistence of integrated proviruses in resting CD4+ T cells that remain in a transcriptionally silent, latent state. One strategy to eradicate latent HIV is to activate viral transcription, followed by elimination of infected cells through virus-mediated cytotoxicity or immune-mediated clearance. We…

Read More

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

06/16/2025

Excerpt from the Press Release: EMERYVILLE, Calif.–(BUSINESS WIRE)–Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected…

Read More

Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-023, a Potential Best-in-Class, Novel CDK4 Selective Inhibitor

06/13/2025

Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced initiation of a Phase 1/2 clinical study of its potential best-in-class cyclin-dependent kinase 4 (CDK4) selective inhibitor, AVZO-023, in patients with advanced or metastatic hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast…

Read More